Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104

Partridge, Ann H.; Archer, Linda L.; Kornblith, Alice B.; Gralow, Julie R.; Grenier, Debjani; Perez, Edith A.; Wolff, Antonio C.; Wang, Xiaofei; Kastrissios, Helen; Berry, Donald A.; Hudis, Clifford A.; Winer, Eric P.; Muss, Hyman B.

doi:10.1200/jco.2009.26.4671

Cited by 118 publications

(93 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Larger group of patients with other types of cancer should be involved in the future to give more reliable information about this association. Cancer stage as well did not show any association with adherence score and this is supported by several previous studies (Partridge et al, 2010;Thivat et al, 2013;Verbrugghe et al, 2013).…”

Section: Adherence To Capecitabine Treatment and Contributing Factorssupporting

confidence: 85%

“…Parallel with earlier studies among capecitabine patients, patient adherence did not seem to be affected by the number of cycle (Partridge et al, 2010;Krolop et al, 2013;Thivat et al, 2013).…”

Section: Adherence To Capecitabine Treatment and Contributing Factorssupporting

confidence: 77%

“…Two other similar studies set even higher cut-off point for adherence to capecitabine which is not less than 100% (Winterhalder et al, 2011;Bhattacharya et al, 2012), since they considered that significant deviation from the actual standard may result in significant effect on efficacy. Meanwhile, two other studies set 80% and above as being adherent (Partridge et al, 2010;Thivat et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Adherence to Capecitabine Treatment and Contributing Factors among Cancer Patients in Malaysia

Zahrina

Norsa’adah²,

Norazwany³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Section: Adherence To Capecitabine Treatment and Contributing Factorssupporting

confidence: 85%

Section: Adherence To Capecitabine Treatment and Contributing Factorssupporting

confidence: 77%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adherence to Capecitabine Treatment and Contributing Factors among Cancer Patients in Malaysia

Zahrina

Norsa’adah²,

Norazwany³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Multiple studies regarding the adherence of patients to oral anticancer agents have been reported (1,2,(4)(5)(6)(7)(8). However, thus far, regimen adherence to tegafur/gimeracil/oteracil potassium (S-1) or capecitabine and multiple tyrosine kinase inhibitors have not been examined.…”

Section: Introductionmentioning

confidence: 99%

Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient setting

Kimura¹,

Nakashima²,

Usami³

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to clarify the adherence and awareness of oral anticancer agents by type and therapeutic purpose in outpatients prescribed with tegafur/gimeracil/oteracil potassium (S-1) or capecitabine. Outpatients undergoing treatment with the S-1 or capecitabine oral anticancer agents at Ogaki Municipal Hospital (Ogaki, Japan) in June 2013 completed a questionnaire survey and the survey findings were evaluated. No significant differences in medication adherence were identified between the patients administered S-1 and the patients administered capecitabine (P= 0.4586). In addition, no significant differences were identified in therapeutic purpose between adjuvant therapy, and advanced and recurrent therapies. However, for S-1 and capecitabine, medication adherence was significantly higher in those undergoing combination therapy compared with those undergoing monotherapy (P=0.0046). In addition, for patients taking S-1, the median age for good adherence was significantly lower than that for insufficient adherence (66.1±10.5 vs. 72.1±7.9 years, respectively; P=0.0035). Furthermore, a significant negative correlation was identified between the awareness score of research regarding the medication and age (n=109; P= 0.0045). In conclusion, for patients treated with S-1 or capecitabine, the type and therapeutic purpose of oral anticancer agents did not affect medication adherence. Elderly patients expressed a low interest in medications and typically exhibited insufficient medication adherence. Therefore, patient guidance by pharmacists is important, as it may result in improved medication adherence and an improved understanding of the treatment side-effects in patients self-administering prescribed drugs. IntroductionIt is important that patients understand the effects of prescribed medicines, as well as the side-effects and methods of administration, as good medication adherence can lead to more effective treatment, improved safety and continuity of treatment in cancer chemotherapy (1-3). Therefore, it is necessary to investigate medication adherence in patients undergoing chemotherapy with consideration of their understanding of the side-effects.Multiple studies regarding the adherence of patients to oral anticancer agents have been reported (1,2,4-8). However, thus far, regimen adherence to tegafur/gimeracil/oteracil potassium (S-1) or capecitabine and multiple tyrosine kinase inhibitors have not been examined. Furthermore, the level of awareness of these medicines, which often corresponds to non-adherence by patients, has yet to be investigated. The side-effects of the aforementioned oral anticancer agents are characterized by the development of skin disorders and digestive system side-effects (9-11). In our previous study, a questionnaire survey was conducted to evaluate factors that may affect medication adherence in patients taking oral anticancer agents (3). It was identified that the medication compliance of patients self-administering oral anticancer agents was adequate, howeve...

show abstract

“…The majority of studies on medication compliance in oncology have focused on oral hormonal therapies in breast cancer 5, 6, 11, 12, 13 even though oral drugs are also frequently used in other cancers 14, 15, 16, 17. In colon cancer, the oral 5‐fluorouracil prodrug known as capecitabine is a commonly prescribed component in a large number of systemic therapy regimens 18, 19, but it has received relatively little focus to date 20, 21, 22, 23. Patients prescribed capecitabine may be at risk of not filling the initial prescription (noninitiation), failing to take the medication as prescribed (nonadherence), or continuing with the drug only temporarily (early discontinuation or nonpersistence) 20, 22.…”

Section: Introductionmentioning

confidence: 99%

Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data

et al. 2016

View full text Add to dashboard Cite

We aimed to examine the frequency of treatment delays as well as the reasons and appropriateness of such delays in early stage colon cancer patients receiving adjuvant capecitabine by comparing data from pharmacy dispensing versus medical records. Patients diagnosed with stage II or III colon cancer from 2008 to 2012 and who received at least two cycle of adjuvant capecitabine were reviewed for treatment delays. Data from pharmacy dispensing and patient medical records were compared. Multivariate regression models were constructed to identify predictors of treatment delays. A total of 697 patients were analyzed: median age was 70 years (IQR 30–89), 394 (57%) were men, 598 (86%) reported Eastern Cooperative Oncology Group 0/1, and 191 (27%) had stage II disease. In this study cohort, 396 (57%) patients experienced at least 1 treatment delay during their adjuvant treatment. Upon medical record review, half of treatment delays identified using pharmacy administrative data were actually attributable to side effects, of which over 90% were considered clinically appropriate for patients to withhold rather than to continue the drug. The most prevalent side effects were hand‐foot syndrome and diarrhea which occurred in 176 (44%) and 67 (17%) patients, respectively. Multivariate analysis revealed a statistically significant association between stage and inappropriate treatment delays whereby patients with stage II disease were more likely to experience drug noncompliance (OR 1.79, 95% CI: 1.27–2.53, P < 0.001) than those with stage III disease. Compliance with adjuvant capecitabine was reasonable. Adherence ascertained from pharmacy administrative data differs significantly from that obtained from medical records.

show abstract

Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104

Cited by 118 publications

References 21 publications

Adherence to Capecitabine Treatment and Contributing Factors among Cancer Patients in Malaysia

Adherence to Capecitabine Treatment and Contributing Factors among Cancer Patients in Malaysia

Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient setting

Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data

Contact Info

Product

Resources

About